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Abstract
Immunodeficiency is a severe therapy-limiting side effect of anticancer chemotherapy resulting from sensitivity of
immunocompetent cells to DNA damaging agents. A central role in the immune system is played by monocytes that
differentiate into macrophages and dendritic cells (DCs). In this study we compared human monocytes isolated from
peripheral blood and cytokine matured macrophages and DCs derived from them and assessed the mechanism of toxicity
of the DNA methylating anticancer drug temozolomide (TMZ) in these cell populations. We observed that monocytes, but
not DCs and macrophages, were highly sensitive to the killing effect of TMZ. Studies on DNA damage and repair revealed
that the initial DNA incision was efficient in monocytes while the re-ligation step of base excision repair (BER) can not be
accomplished, resulting in an accumulation of DNA single-strand breaks (SSBs). Furthermore, monocytes accumulated DNA
double-strand breaks (DSBs) following TMZ treatment, while DCs and macrophages were able to repair DSBs. Monocytes
lack the DNA repair proteins XRCC1, ligase IIIa and PARP-1 whose expression is restored during differentiation into
macrophages and DCs following treatment with GM-CSF and GM-CSF plus IL-4, respectively. These proteins play a key role
both in BER and DSB repair by B-NHEJ, which explains the accumulation of DNA breaks in monocytes following TMZ
treatment. Although TMZ provoked an upregulation of XRCC1 and ligase IIIa, BER was not enhanced likely because PARP-1
was not upregulated. Accordingly, inhibition of PARP-1 did not sensitize monocytes, but monocyte-derived DCs in which
strong PARP activation was observed. TMZ induced in monocytes the DNA damage response pathways ATM-Chk2 and ATR-
Chk1 resulting in p53 activation. Finally, upon activation of the Fas-receptor and the mitochondrial pathway apoptosis was
executed in a caspase-dependent manner. The downregulation of DNA repair in monocytes, resulting in their selective
killing by TMZ, might impact on the immune response during cancer chemotherapy.
Citation: Bauer M, Goldstein M, Heylmann D, Kaina B (2012) Human Monocytes Undergo Excessive Apoptosis following Temozolomide Activating the ATM/ATR
Pathway While Dendritic Cells and Macrophages Are Resistant. PLoS ONE 7(6): e39956. doi:10.1371/journal.pone.0039956
Editor: Roland Jacobs, Hannover Medical University (MHH), Germany
Received January 27, 2012; Accepted May 29, 2012; Published June 29, 2012
Copyright:  2012 Bauer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants of the Deutsche Forschungsgemeinschaft, KA724/13 and KA724/14. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kaina@uni-mainz.de
. These authors contributed equally to this work.
Introduction
Immunosuppression is one of the most severe side effects of
chemotherapy endangering lives of patients who undergo medical
cancer treatment. In general, the high proliferation rate of the
immune response progenitor cells is considered accountable for
their sensitivity to DNA damaging agents that are used for cancer
treatment. Surprisingly, little attention has been paid yet to the
toxicity of chemotherapeutic drugs in mature immune response
cells. Originating from bone marrow precursor cells mature
monocytes enter the blood stream where they circulate for several
days [1]. After entering the tissue they differentiate into DCs and
macrophages, both of which play an important role in the immune
response.
In the course of the current research we investigated the
mechanism of cytotoxicity of the chemotherapeutic anticancer
drug temozolomide (TMZ, Temodar) in human monocytes freshly
isolated from peripheral blood. Methylating agents, including
TMZ, induce a variety of N- and O-DNA alkylations with N7-
methylguanine to be the most frequent one [2]. O
6-methylguanine
is a minor adduct, which is repaired by O
6-methylguanine-DNA
methyltransferase (MGMT) [3]. If this repair mechanism fails O
6-
methylguanine results in the formation of toxic DSBs due to faulty
mismatch repair during proliferation [4]. On the other hand, N7-
methylguanine and other N-methylpurines like the replication
blocking N3-methyladenine are repaired by base excision repair
(BER) [5]. In a previous work we reported that human monocytes
express the BER factors XRCC1 and ligase IIIa at a low, nearly
undetectable level, which was restored during the ex vivo
differentiation of monocytes to dendritic cells (DCs) [6], suggesting
a defect of BER in monocytes. Indeed, monocytes were
hypersensitive to DNA methylating agents, while DCs derived
from them were not [6].
As mentioned above, non-toxic DNA lesions such as DNA
alkylation adducts can be converted into DNA single-strand (SSB)
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39956and double-strand breaks (DDB) resulting in cytotoxicity. SSB are
detected by the ATR kinase, while DSB activate the ATM kinase.
A variety of signaling pathways is activated in turn, resulting in cell
cycle arrest and apoptosis, which in many cases is p53-dependent
(for review see [7]). Here, we extend our previous observation by
showing that monocytes strongly respond to TMZ. They do not
express PARP-1, which is another BER, SSB and DSB repair
factor [8,9]. Similar to XRCC1 and ligase IIIa, PARP-1
expression is upregulated during differentiation of monocytes into
DCs and macrophages. We further demonstrate that monocytes
can initiate BER by incising the DNA. However, lack in XRCC1,
PARP-1 and ligase IIIa prevents subsequent DNA re-ligation
resulting in accumulation of SSBs. Following TMZ treatment the
inability to complete DNA repair finally results in an accumulation
of DSBs in monocytes, but not in DCs and macrophages. Our
data bear important clinical implications, suggesting that mature
monocytes may be specifically killed during TMZ based cancer
therapy, whereas DCs and macrophages might be protected.
Results
In order to study the TMZ sensitivity and DNA damage
response in human monocytes and their derivatives, macrophages
and immature DCs, monocytes were isolated from peripheral
blood of healthy donors and either left untreated or treated with
IL-4 and GM-CSF or GM-CSF alone in order to induce the
differentiation of DCs or macrophages, respectively (Fig. 1A
showing the typical shape and surface staining of monocytes and
macrophages with CD14). The cell populations from each
preparation were characterized by flow cytometry (see Material
and Methods). It is noteworthy that, except for small populations,
mature monocytes, DCs and macrophages do not proliferate in vivo
[10]. In fact, as revealed by flow cytometry (Fig. 1B), all three cell
types were arrested in G1 and maintained in vitro in a non-
proliferative state. Treatment with the methylating anticancer
drug TMZ resulted in a significant induction of apoptosis in
monocytes, while DCs and macrophages were resistant to this
agent (Fig. 1C).
DNA methylation following TMZ exposure yields different
lesions with N7-methylguanine to be the most frequent one to
appear [2]. Although O
6-methylguanine was shown to be
responsible for the toxicity of methylating agents in proliferating
cells [4], this lesion is unlikely to be important in our cellular
system since the cells do not proliferate. Also, monocytes express a
high level of MGMT compared to macrophages and DCs and are
therefore able to remove O
6-methylguanine from DNA [11]. N7-
MeG, N3-MeG and the toxic lesion N3-MeA are repaired by
BER. This prompted us to determine the expression level of BER
enzymes and we found, similar to our previous observation [6],
that monocytes express XRCC1 and ligase IIIa at a very low (non-
detectable) level (Fig. 2A,B). Expression of these BER factors was
evoked, however, following cytokine treatment and was completely
restored on day 6 (Fig. 2A) and day 3 (Fig. 2B) during maturation
of monocytes into DCs and macrophages, respectively. We also
observed that monocytes lack PARP-1, an important factor of
BER and SSB repair, and that expression of PARP-1 was restored
concomitant with XRCC1 and ligase IIIa during the maturation
of monocytes to DCs and macrophages (Fig. 2A,B).
Next we wished to determine whether treatment with TMZ has
an effect on the expression of the repair proteins. TMZ treatment
resulted in decreased PARP-1 levels in DCs and macrophages.
Surprisingly, it also resulted in an increase in the level of XRCC1
and ligase IIIa in monocytes (Fig. 2C). Thus it appears that TMZ
treatment provokes upregulation of XRCC1 and ligase IIIa, but
Figure 1. Differentiation of monocytes into DCs and macro-
phages and their killing response. (A) Images of monocytes and
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activity in monocytes following genotoxic stress by TMZ. Without
TMZ treatment, monocytes were unable to restitute the cleaved
oligonucleotide (Fig. 2D). Despite the increase in XRCC1 and
ligase IIIa level following TMZ treatment, the BER activity in
monocytes was not restored (Fig. 2D). Thus, the initial incision of
the lesion (yielding the 19mer fragment) and the following
processing (yielding the 19+1mer fragment) was highly efficient
in monocytes, while the XRCC1/ligase IIIa-dependent re-ligation
step (resulting in the restoration of the 39mer) was abrogated
(Fig. 2D and 2E for quantification). The accumulation of the
19+1mer fragment reflected the increased level of SSBs in
monocytes due to incomplete BER.
The lack of PARP-1 in monocytes let us to predict that
monocytes are unable to generate poly(ADP)ribose following
genotoxic stress. This is indeed the case as monocytes did not
display PAR staining while DCs and macrophages were heavily
PAR stained upon treatment with hydrogen peroxide, which
induces oxidative DNA damage (Fig. 3A). The PARP-1 inhibitor
olaparib [12] abolished the formation of PAR nearly to
completion (Fig. 3A). As expected, olaparib had no effect on the
killing response of monocytes treated with TMZ, while it
enhanced cell death in DCs and macrophages (Fig. 3B). We
should note that the effect of olaparib in DCs and macrophages on
TMZ-induced cell death was not dramatic and the cells did not
reach the sensitivity level of monocytes, which is explained by the
finding that monocytes lack in addition to PARP-1 other BER
proteins that exacerbate the deficiency of PARP-1. Overall, the
data supports the notion that the lack of PARP-1 together with
XRCC1, ligase IIIa and DNA-PKcs is critically involved in the
hypersensitivity of monocytes to TMZ.
Following DNA methylation, SSBs can be converted to toxic
DSBs during the S phase [13]. Monocytes, however, are non-
proliferating cells. In these cells an induction of a large amount of
SSBs can result in DSB formation if two SSBs, one on each DNA
strand, face each other. Since it is reasonable to posit that the
cytotoxicity observed in monocytes originates from DSBs we
determined the formation of cH2AX foci that reflects DSB
formation [14]. A similar formation of cH2AX foci was observed
in monocytes, DCs and macrophages 3 h after TMZ treatment
(Fig. 4) indicating that DSBs are formed in all three cell types
following DNA methylation. However, while the resolution of
cH2AX foci in DCs and macrophages indicated that repair of the
DNA lesions occurred in these cells, DSBs remained in monocytes
for as long as 24 h post-treatment (Fig. 4), indicating a defect in
DSB repair.
Next, we addressed the question of how apoptotic cell death is
executed in monocytes following TMZ-induced DNA lesions.
DSBs activate the ATM kinase, which in turn can activate p53
either directly by phosphorylation or via activation of the Chk2
kinase [7]. SSBs activate the ATR kinase that phosphorylates p53
either directly or via Chk1 activation [7]. In Fig. 5A it is shown
that in monocytes following TMZ treatment both ATM and ATR
are activated, which is reflected by autophosphorylation of these
kinases and by consecutive phosphorylation of the histone H2AX
(forming cH2AX). We also observed activation of Chk1 and Chk2
and a strong increase in p53 protein level (Fig. 5A). Applying a
number of specific small molecule inhibitors of ATM, ATR, Chk1
and Chk2 we show that all these DNA damage response (DDR)
factors contribute to TMZ-induced apoptosis in monocytes since
apoptosis was reduced following their cotreatment with TMZ
(Fig. 5B). Inhibition of Chk1, Chk2 and PI-3 kinases attenuated
the level of induction of p53 protein (Fig. 5C) indicating that these
factors act upstream of p53.
We went on to investigate which pathway signals apoptosis in
monocytes downstream of p53. Following TMZ treatment we
observed an increase in the death receptor Fas (CD95, Apo-1).
FasR upregulation following TMZ was observed on mRNA level
(Fig. 6A for semi-quantitative PCR and Fig. 6B for qRT-PCR),
which was confirmed on the level of the protein (Fig. 6C). At the
same time we observed an increase in the level of membrane-
bound (mFasL) and soluble (sFasL) Fas ligand and cleavage of
caspase-8 (Fig. 6C). The data strongly suggest the involvement of
the exogenous Fas-driven pathway in TMZ-induced monocyte
toxicity. Downstream we observed activation of the executing
caspases -3 and -7 (Fig. 6D). There was also Bcl-2 decline and
caspase-9 activation (Fig. 6E) indicating the mitochondrial
pathway to be involved as well. Bax and XIAP were not changed
in expression (Fig. 6F).
The involvement of caspases and p53 in TMZ-induced
apoptosis in human primary monocytes was confirmed by
inhibitor experiments showing that the transcriptional inhibitor
of p53, pifithrin-a, as well as the pan-caspase inhibitor Boc-VAD-
fmk and an antagonizing Fas receptor antibody significantly
attenuated the apoptotic response (Fig. 6G). Overall, the data
showed that TMZ induces the ATM/ATR/p53 response in
human monocytes that results downstream in activation of the
endogenous and exogenous apoptosis pathway.
Discussion
Cancer patients who undergo chemotherapy frequently suffer
from immunosuppression, making it one of the most important
dose-limiting side effects. The reason for this is believed to be that
chemotherapeutic drugs that target DNA require DNA replication
in order to become cytotoxic [15] and, therefore, cells are most
sensitive towards most types of DNA lesions in the S phase of the
cell cycle. Based on this, a current paradigm states that highly
proliferative tissues such as the tumor itself and bone marrow are
most responsive to chemotherapy. Although immune response
precursor cells are known to be very susceptible, which is thought
to be due to hematopoetic stem cell toxicity [16], the majority of
mature immune response cells does not proliferate and might thus
be considered resistant to chemotherapy. Challenging this
hypothesis, we investigated the mechanism of cytotoxicity of the
chemotherapeutic drug TMZ, which is representative for meth-
ylating agents and used in glioma and malignant melanoma
therapy, in non-proliferating human monocytes freshly isolated
from peripheral blood, and DCs and macrophages derived from
them by cytokine maturation.
Here, we report that primary monocytes are highly sensitive to
TMZ while DCs and macrophages (derived in each experiment
from the same donor) are resistant. TMZ is a methylating agent
inducing N- and O-alkylations in the DNA. Although N7-
methylguanine is the most frequent lesion induced by methylating
agents [2] O
6-methylguanine is responsible for the cytotoxicity in
proliferating cells due to faulty MMR and replication-dependent
DCs and macrophages derived from them by cytokine stimulated
maturation. Blue, nuclear staining with ToPro3; red staining on
monocytes and macrophages, CD14 surface marker, which is not
expressed on macrophages. (B) Representative histograms of mono-
cytes, DCs and macrophages stained with propidium iodide and
measured by flow cytometry. C, non-treated; TMZ, treated with 0.6 mM
TMZ and measured 72 h after treatment. (C) Analysis of apoptosis 72 h
following 0.6 mM TMZ treatment by quantification of the subG1
fraction of cells by flow cytometry. (**p,0.01, ***p,0.001, t-test
comparing monocytes with DCs and macrophages).
doi:10.1371/journal.pone.0039956.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39956DSB formation [17,18]. Since CD14
+ monocytes isolated from
peripheral bloood, and DCs and macrophages derived from them
(defined by the surface markers CD3, CD19, CD14, CD80,
CD86, [19]) were cultured under conditions that do not allow
proliferation, a significant contribution of O
6-methylguanine to
the toxicity in these cells is unlikely. Accordingly, inhibition of
MGMT, which is highly expressed in monocytes, had no effect on
the cytotoxicity in these cells following treatment with the
methylating mutagen MNNG [6]. Therefore, we focused on N7-
methylguanine and N3-methyladenine as potentially toxic lesions.
Since these adducts are repaired by BER that requires XRCC1,
ligase IIIa and PARP-1, we conclude that the hypersensitivity to
Figure 2. Expression of BER proteins in monocytes and follow-up during differentiation of monocytes in DCs and macrophages and
BER activity in monocytes. Expression of PARP-1, XRCC1 and ligase IIIa during maturation of monocytes into DCs (A) and macrophages (B)
analyzed by immunoblots. (C) Expression of PARP-1, XRCC1 and ligase IIIa in monocytes, DCs and macrophages without treatment and 24 and 48 h
following treatment with 0.6 mM TMZ. (D) BER assay in untreated and TMZ treated monocytes 24 and 48 h post-treatment. The 39mer fragment
represents the full-length oligonucleotide. The 19mer and the 19+1 fragment are products of the initial incision and processing, respectively.
Restoration of the 39mer fragment represents the re-ligation step. For positive, repair competent, control we used extracts of DCs. (E) Quantification
of the full-length fragment shown in (D). The relative amount of the 39mer is shown as a function of time following TMZ.
doi:10.1371/journal.pone.0039956.g002
Figure 3. PARP activation and effect of PARP inhibition in monocytes, macrophages and DCs. (A) Cells were treated with hydrogen
peroxide (10 mM for 10 min) or olaparib (0.5 mM) 1 h prior to hydrogen peroxide (10 mM, 10 min), fixed and stained with anti-poly(ADP)ribose (PAR)
antibody. Green, anti-PAR; blue, nuclear staining with ToPro3. (B) Cells were treated with temozolomide (0.6 mM) or olaparib (0.5 mM) 1 h prior to
temozolomide and apoptosis was measured by subG1 flow cytometry 72 h later. Basal levels were subtracted and the induced levels are shown. Data
are the mean of three independent experiments +/2S.D.
doi:10.1371/journal.pone.0039956.g003
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these BER factors. These repair proteins are upregulated in DCs
and macrophages and therefore DNA repair, i.e. the re-ligation
step of BER, is restored upon maturation. Interestingly, following
genotoxic stress by TMZ treatment the level of XRCC1 and ligase
IIIa increased in monocytes, which extends a previous finding
showing that XRCC1 is upregulated in in vitro cultured monocyte-
like cells following methyl methanesulfonate treatment [20].
Nonetheless, these TMZ-stimulated alterations in protein expres-
sion did not improve the DNA break re-ligation efficiency in
monocytes following TMZ treatment. The reason lies likely in the
lack of PARP-1, which was not upregulated following TMZ
treatment. PARP-1 is functionally active in macrophages and
DCs, but not monocytes, as shown by extensive PAR formation in
macrophages and DCs following genotoxic stress. Inhibition of
PARP-1 by olaparib sensitized macrophages and DCs to TMZ,
but not to the level of monocytes, which is explained by the
multiple repair defect in these cells. We should note that DNA-
PKcs is also lacking in monocytes [19]. In complementation
studies with a bicistronic vector of XRCC1-ligase IIIa we were
unable complement the hypersensitive phenotype of monocytes
(unpublished data), which is to be expected taking into account the
severe DNA repair defect in these cells.
Although in our system DSBs will not arise during DNA
replication (as the cells do not replicate), they can emerge when
two SSBs are facing each other, which may happen if a large
amount of SSBs accumulates in the cell. This appears to be the
case as indicated by the time course of formation of cH2AX foci in
monocytes, DCs and macrophages after TMZ treatment. While
cH2AX foci were resolved in DCs and macrophages 24 h
following TMZ treatment, indicating DNA repair, DSBs contin-
ued to be present in monocytes. Thus, we conclude that TMZ-
induced N-methylpurines, that are subject to removal by N-
methylpurine-DNA glycosylase, are converted into SSBs due to
incision of DNA by the BER machinery and a fraction of them will
result in DSBs as the result of SSB accumulation in overlapping
repair patches. It is important to note that monocytes express a
normal level of N-methylpurine-DNA glycosylase (MPG alias
AAG) and apurinic endonuclease and are thus able to remove N-
methylpurines from DNA [6]. While DCs and macrophages can
repair the subsequently formed SSBs, monocytes are defective in
the ligation of these repair intermediates as this repair step requires
XRCC1 and ligase IIIa. Additionally, DSBs formed in overlap-
ping repair patches are not repaired as a subpathway of DSB
repair in non-proliferating cells is B-NHEJ, which rests on
XRCC1, ligase IIIa and PARP-1 [21]. We should note that
homologous recombination does not play a role since the cells
were not proliferating. The data leads us to conclude that the
hypersensitivity of monocytes to methylating anticancer drugs is a
result of a defect in BER and NHEJ.
Regarding the mechanism of cell kill, we found that following
TMZ treatment the ATM/ATR-Chk1/Chk2-p53 pathway was
activated in monocytes resulting in Fas (CD95, Apo-1) receptor
upregulation and caspase-8 activation. We also observed Bcl-2
Figure 4. Accumulation of DSBs in monocytes, but not in DCs and macrophages after TMZ treatment. Immunostaining of cH2AX foci at
indicated time points following treatment with 0.6 mM TMZ in monocytes, DCs and macrophages. Blue, nuclear staining with ToPro3; green,
phospho-H2AX staining with anti-cH2AX.
doi:10.1371/journal.pone.0039956.g004
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exogenous and endogenous apoptotic pathway, both of which can
be activated by DNA damage [22]. The Fas pathway seems to play
an important role in the activation of apoptosis following DNA
damage in hematopoetic cells as it becomes activated after
exposure to mafosfamide, a DNA cross-linking drug [23],
oxidative stress [19] and other genotoxic insults [24].
Our results bear implications for cancer treatment. We
should note that monocytes are not only TMZ but also ionising
radiation (IR) hypersensitive [19], which is important to note
since TMZ is applied concomitantly with IR in glioma therapy
[25]. Hypersensitivity of monocytes towards TMZ (and IR)
could be at least in part responsible for the immunosuppression
in patients who undergo chemotherapy, leading to a depletion
of monocyte derived macrophages and DCs, which are
supposed to play a role in tumor host defense [26,27,28]. At
the same time our data (this paper and [6,19]) indicate that
immature and mature DCs and macrophages exhibit a
significant defense by efficient DNA repair and thus are
protected against methylating agents and IR-induced cell death.
This is notably important for immuno-vaccination of patients
with immature DCs [29], which are derived from monocytes in
vitro according to the same protocol we used in our experiments
[30]. Clinical studies observing monocyte counts in patients
receiving TMZ or other methylating drugs such as dacarbazine,
procarbazine or streptozotozine would provide further evidence,
and these studies are in progress. The finding that both Chk1
and Chk2 inhibitors were able to attenuate the killing response
of monocytes following TMZ bears the potential of protecting
monocytes from therapy related side effects. These inhibitors are
being clinically tested in combination with chemotherapy [31].
Since inhibition of these kinases reduced apoptosis in monocytes
we suggest the possibility that inhibitors of Chk1 and Chk2 may
protect monocytes during cancer treatment and compensate
Figure 5. Activation of ATM, ATR, p-H2AX, Chk1, Chk2 and p53 in monocytes. (A) Western Blot analysis of DDR proteins and p53 in
monocytes not treated (zero time) and treated with 0.6 mM TMZ. (B) Quantification of the subG1 fraction in monocytes co-treated with 0.6 mM TMZ
and the indicated kinase inhibitors for 72 h. (C) Western Blot analysis of p53 activation in monocytes co-treated with 0.6 mM TMZ and kinase
inhibitors as indicated for 48 h. Cells were pretreated with 10 mM wortmanin, 10 mM Ku55933, 10 mM Chk1 and 10 mM Chk2 inhibitor for 1 h prior to
TMZ addition. Cells were post-treated with 10 mM Ku55933, 10 mM Chk1 and 10 mM Chk2 inhibitor every 24 h following TMZ treatment.
doi:10.1371/journal.pone.0039956.g005
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Recently, new approaches have been developed to inhibit
DNA damage dependent p53 activation using short, single-
strand oligonucleotides that target this 59-39-UTR base-pairing
region of p53 mRNA and block its translation [32]. Once this
approach will be applicable to cancer patients in order to
protect bone marrow from side effects of chemotherapy our
data suggest that mature monocytes will benefit from this
treatment as well.
Figure 6. Mitochondrial and FasR pathway activation in monocytes resulting in caspase dependent apoptosis. (A) Representative
image of semiquantitative RT-PCR analysis of FasR mRNA expression in monocytes treated with 0.6 mM TMZ. (B) Quantitative RT-PCR analysis of FasR
mRNA expression in monocytes treated with 0.6 mM TMZ. (C, D, E, F) Western Blot analysis of Fas receptor, membrane bound Fas ligand and cleaved
caspase-8 (C) activated caspase-3 and -7 (D) Bcl-2 and activated caspase-9 (E) and BAX and XIAP (F) in monocytes treated with 0.6 mM TMZ. (G)
Quantification of the subG1 fraction in monocytes co-treated with 0.6 mM TMZ and indicated inhibitors or antibody for 72 h. Cells were pretreated
with 30 mM pifithrin-a,5 0mM Boc-VAD-fmk and 1 mg/ml anti FasR antibody for 1 h prior to the addition of TMZ and post-treated with 15 mM
pifithrin-a,2 5mM Boc-VAD-fmk and 0.5 mg/ml anti FasR antibody every 24 h following TMZ treatment.
doi:10.1371/journal.pone.0039956.g006
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Chemicals
Temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazabicy-
clo[4.3.0]nona-2,7,9-triene-9-carboxamide; Schering-Plough,
Whitehouse Station, NJ) was prepared and used as described
previously [33]. Wortmannin, Ku 55933, Isogranulatimide and
Chk2inhibitorII,Pifithrin-a,Boc-VAD-fmk,neutralizingFasR-AB
and Protein G were obtained from Calbiochem (Schwalbach,
Germany). Wortmannin is an inhibitor of phosphatidylinositol 3-
kinasefamilylikeATMandATR[34].Ku55933actsasaninhibitor
of ATM kinase [35,36]. Isogranulatimide is a Chk1 inhibitor [37].
Pifithrin-a inhibitsthe transcriptional activity ofp53[38].
Generation of Monocytes, Dendritic Cells and
Macrophages from Peripheral Blood Mononuclear Cells
(PBMC)
PBMC were isolated by Ficoll-Hypaque density gradient
centrifugation from buffy coats of healthy blood donors obtained
from the blood bank of University Hospital of Mainz. They were
seeded in six-well plates (Corning/Costar, Bodenheim, Germany)
at 1–1.5610
7 cells/3 ml/well in RPMI 1640 (PAA, Pasching,
Austria) containing 1.5% autologous plasma and incubated for
60 min at 37uC, 5% CO2. Non-adherent cells were removed and
the remaining cells, which represent monocytes [30] were
harvested or further cultured in X-VIVO-15 with 800 U/ml
GM-CSF (Bayer Healthcare Pharmaceuticals, Seattle, USA) and
50 U/ml IL-4 (Miltenyi Biotec, Bergisch-Gladbach, Germany).
Cells were fed on third and sixth day with X-VIVO-15, 1600 U/
ml GM-CSF and 50 U/ml IL-4. After 1 week, immature DCs
were harvested. For generation of macrophages PBMC were
seeded in six-well plates at 0.5610
7 cells/3 ml/well in RPMI 1640
containing 1.5% autologous plasma for 60 min (37uC, 5% CO2).
Non-adherent cells were removed and the remaining cells were
further cultured in X-VIVO-15 with 800 U/ml GM-CSF.
Macrophages were harvested after 6 days. All cell preparations
were checked as to cell surface markers by flow cytometry, and
preparations that were of low purity (,75%) were excluded.
Flow Cytometric Analysis
For phenotyping, monocytes, dendritic cells and macrophages
were carefully washed in cold PBS with 0.1% BSA and incubated
for 20 min at 4uC with each mAB (5 mg/ml). After washing with
cold PBS/BSA the cells were analyzed by flow cytometry
(FACSCalibur, CellQuest software, BD Biosciences, Mountain
View, CA) with data being collected on 10
4 viable cells. The
following antibodies (mAB) were used for immunofluorescence
staining. Mouse IgG: CD14-PE (TU ¨K4), CD3-PE (BW264/56),
CD19-PE (LT19; Miltenyi Biotec, Bergisch-Gladbach, Germany),
CD80-PE (B7-1), CD86-PE (B7-2), HLA-DR-FITC (eBioscience,
San Diego, USA); and mouse-specific isotypes, IgG-PE (S43.10;
Miltenyi Biotec, Bergisch-Gladbach, Germany) and IgG-FITC
(679.1Mc7; Beckman Coulter, Fullerton, USA).
Quantification of Apoptosis
Apoptosis was measured by subG1 assay. After treatment with
TMZ, pretreated or not pretreated with O
6-benzylguanine, mono-
cytes, DCs and macrophages were washed in PBS, fixed in 70%
ethanol for a minimum of 30 min at 220uC. DNA in the cells was
stained with propidium iodide (16.5 mg/ml) in PBS after RNase
(0.03 mg/ml)digestion.Foreachsample10
4cellswereanalyzedona
FACSCalibur(BectonDickinson).Thenumberofapoptoticcellsper
sample was calculated using the computer program WinMDI 2.9
(Joseph Trotter). The cells were treated with 0.5 mM of the PARP
inhibitor olaparib (AZD2281, Selleckchem) 1 h before TMZ
treatment [12]. The samples were analyzed and calculated as
described aboveon a FACSCanto (BectonDickinson).
Immunostaining of Cells
Prior to immunostaining cells were fixed with 4% paraformal-
dehyde (16PBS, 4% paraformaldehyde) for 20 min. Fixed cells
were permeabilized with 0.5% Triton-X100/PBS for 10 min.
Blocking was done in PBST (16PBS, 0.1% Tween 20) containing
4% BSA for 10 min at room temperature. Antibodies were diluted
in PBST containing 2% BSA. Between application of primary and
secondary antibodies washing steps were performed in PBST for
15 min. Incubations with all antibodies were performed for one
hour at room temperature. Phosphorylated H2AX (ser139,
cH2AX) was detected with monoclonal mouse anti-phoshpo-
cH2AX (Ser 139) antibody (Millipore, Billerica MA, USA) and
then with goat anti-mouse antibody F(ab’)2 fragment conjugated
with AlexaFluor488 (Invitrogen, Oregon, USA). Nuclei were
counterstained using 1 mM ToPro3 (Invitrogen, Oregon, USA),
staining ocuured for 15 min in the dark; preparations were
mounted in antifade medium and sealed with nail polish. The cells
were treated 1 h with 0.5 mM olaparib in X-VIVO-15 and
afterwards for 10 min with 10 mM H2O2 (Roth) in PBS. After
fixation with methanol/acetic acid (3:1) for 5 min, the cells were
stained with a PAR (poly ADP-ribose) mouse antibody (kind gift of
Dr. Bu ¨rkle, Konstanz) and with goat anti-mouse antibody
conjugated with AlexaFluor488 (Invitrogen) in 5% milk powder
in PBS with 0,05% Tween 20 [39]. For the CD14
+ staining, cells
were fixed with methanol, aceton and paraformaldehyde, blocked
with normal goat serum (Invitrogen) and incubated with CD14
mouse monoclonal antibody (Abcam) and then with Cy
TM3-
conjugated AffiniPure goat anti-mouse IgG (H+L) (Jackson
ImmunoResearch) in PBS with 1% BSA. The cells were analyzed
with LSM710 (Carl Zeiss, Oberkochen, Germany).
In vitro BER-assay
BER efficiency after treatment with temozolomide in monocytes
was measured as described [19,40].
Preparation of Whole Cell Extracts and Western Blot
Analysis
Monocytes, DCs and macrophages were harvested, washed
once with ice-cold PBS, and lysed on ice in an appropriate amount
of lysis buffer containing 50 mM Tris-HCl (pH 7.5), 250 mM
NaCl, 1 mM EDTA, 0.1% Triton X-100, 2 mg/ml aprotinin,
2 mg/ml leupeptin, 1 mg/ml pepstatin and 97 mg/ml PMSF. After
30 min incubation, lysates were centrifuged at 13.000 g and 4uC
for 20 min and the supernatant was recovered. The protein
concentration was determined according to Bradford [41]. Cell
extract (30 mg) was separated on a 10% or 7.5% SDS polyacryl-
amide gel at 100 V and was blotted onto a nitrocellulose
membrane for 1 h at 300 mA using buffer composed of
25 mmol/L Tris-HCl, 86 mmol/L glycine, and 20% methanol.
The antibodies used were pATM Ser1981,p - cH2AX (Ser 139)
(Millipore, Billerica MA, USA), pChk1 Ser317 (Bethyl, Montgom-
ery TX, USA), pChk2 Thr68 (Epitomics, Burlingame CA, USA),
p53 (Dianova, Hamburg, Germany), pATR Ser428, Chk1, Chk2,
XIAP, Cleaved Caspase-8, Cleaved Caspase-3, Cleaved caspase-7
(Cell signaling, Danvers, MA USA), XRCC1 (Abcam, Cambridge,
UK), ligase IIIa, Poly(ADP-ribose) polymerase (PARP), FasL, Bcl-
2 (BD Biosciences), FasR, Bax and ERK2 (Santa Cruz Biotech-
nology, Heidelberg, Germany) as protein loading control.
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time RT-PCR
Total RNA was isolated from cells using the RNA II Isolation
Kit from Machery and Nagel. 1 mg RNA was transcribed into
cDNA using the Reverse-iT 1st Strand Synthesis Kit (ABgene,
Surrey, UK). Primer sequences used for PCR were as follows: fasR
(up, 59-AAGGGATTGGAATTGAGGAAGACTG-39; low, 59-
GTGGAATTGGCAAAAGAAGAAGACA-39) and gapdh (up, 59-
CCCCTCTGGAAAGCTGTGGCGTGAT-39; low, 59-
GGTGGAAGAGTGGGAGTTGCTGTTGA-39), which was
used as loading control. Real-time PCR was performed using
the SensiMix Plus SYBR & Fluorescein Kit (Bioline) and the
MyIQ real-time PCR cycler (BioRad). Primer sequences used for
real-time RT-PCR were as follows: fasR (up, 59-TTATCT-
GATGTTGACTTGAGTAA-39; low, 59-GGCTTCATTGA-
CACCATT-39) and ß-Actin (up, 59-TGGCATCCACGAAAC-
TACC-39; low, 59-GTGTTGGCGTACAGGTCTT-39), which
was used as loading control.
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